HC Wainwright restated their buy rating on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a report issued on Friday, March 9th. They currently have a $12.00 target price on the biotechnology company’s stock.
A number of other research analysts have also commented on PIRS. ValuEngine lowered shares of Pieris Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, December 1st. BidaskClub raised shares of Pieris Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, December 27th. Finally, William Blair started coverage on shares of Pieris Pharmaceuticals in a report on Wednesday, January 17th. They set an outperform rating for the company. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Pieris Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $10.00.
Shares of Pieris Pharmaceuticals (PIRS) traded down $0.07 during trading hours on Friday, reaching $6.81. 1,484,355 shares of the company’s stock traded hands, compared to its average volume of 960,542. The company has a market cap of $370.52, a PE ratio of -16.61 and a beta of 1.50. Pieris Pharmaceuticals has a 52-week low of $2.26 and a 52-week high of $9.75.
In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 147,635 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $5.70, for a total value of $841,519.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 1,865,152 shares of company stock valued at $13,478,142. Corporate insiders own 4.05% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Creative Planning increased its position in shares of Pieris Pharmaceuticals by 18.2% during the fourth quarter. Creative Planning now owns 78,025 shares of the biotechnology company’s stock worth $589,000 after buying an additional 12,000 shares during the period. Acadian Asset Management LLC grew its holdings in Pieris Pharmaceuticals by 14.0% in the fourth quarter. Acadian Asset Management LLC now owns 116,154 shares of the biotechnology company’s stock worth $877,000 after purchasing an additional 14,263 shares during the period. Cetera Advisor Networks LLC acquired a new stake in Pieris Pharmaceuticals in the fourth quarter worth $124,000. New York State Common Retirement Fund grew its holdings in Pieris Pharmaceuticals by 107.5% in the third quarter. New York State Common Retirement Fund now owns 33,000 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 17,100 shares during the period. Finally, Wells Fargo & Company MN acquired a new stake in Pieris Pharmaceuticals in the third quarter worth $105,000. Institutional investors own 47.19% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Pieris Pharmaceuticals (NASDAQ:PIRS) Earns Buy Rating from HC Wainwright” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/03/17/hc-wainwright-reiterates-buy-rating-for-pieris-pharmaceuticals-pirs.html.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.